Evidence map›Paper›PMID 40232378›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway.

Arya Afrooghe, Elham Ahmadi, Ali Lesani, Mahya Soleymani Mehranjani, Mohammad Elahi, Mohammadreza Babaei, Maryam Shayan, Hamed Shafaroodi, Razieh Mohammad Jafari, Alireza Foroumadi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arya Afrooghe *Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Elham Ahmadi *Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Ali LesaniExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mahya Soleymani MehranjaniExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad ElahiExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammadreza BabaeiExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Maryam ShayanExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Hamed ShafaroodiExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Razieh Mohammad JafariExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Alireza ForoumadiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, Iran.
Mohammad Amin ManaviExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Ahmad-Reza DehpourExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. dehpour@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to investigate whether psilocin, the bioactive metabolite of the well-known psychedelic, psilocybin, may have antipruritic effects in mice by interfering with the kynurenine pathway and interacting with 5-HT2A receptors. Eight mice were randomly assigned to each of the study groups receiving either normal saline, compound 48/80, psilocin (0.3, 1, and 3 mg/kg), or psilocin (1 mg/kg) + 1-MT (0.3 mg/kg). The scratching bouts were documented in each group. The hallucinogenic properties of psilocin were documented using the head-twitch response (HTR) test. To confirm their involvement, we also quantified the expression levels of TNF-α, TLR-4, indoleamine-2,3-dioxygenase (IDO), and 5-HT2A receptors across various study groups. We found that psilocin (1 mg/kg) exerted the most significant antipruritic and hallucinogenic effects (P < 0.0001). The activity of 5-HT2A receptors in the skin tissue of mice was confirmed by western blot. When psilocin (1 mg/kg) was given together with 1-MT (0.3 mg/kg), the antipruritic effects became more pronounced as compared to when psilocin was given alone (P < 0.05). TLR-4 and TNF-α expression levels considerably reduced after psilocin was applied, both alone and together with 1-MT (P < 0.05, P < 0.01, respectively). We also observed significantly decreased activity of IDO in the treatment groups (P < 0.05, P < 0.01 after giving psilocin alone, and together with 1-MT, respectively). To our knowledge, this is the first study to confirm the effectiveness of psychedelics in battling pruritus. Our findings offer a novel repositioning for psilocin. This may be particularly beneficial for psychological conditions accompanied by pruritus.

Indexed as

AntipruriticsHallucinogensKynureninePruritusPsilocybinReceptor, Serotonin, 5-HT2AAnimalsIndoleamine-Pyrrole 2,3,-DioxygenaseMaleMicePolycyclic SesquiterpenesSignal TransductionToll-Like Receptor 4Tumor Necrosis Factor-alphaAntipruriticsHallucinogensIndoleamine-Pyrrole 2,3,-DioxygenaseKynureninePolycyclic SesquiterpenespsilocinPsilocybinReceptor, Serotonin, 5-HT2ATlr4 protein, mouseToll-Like Receptor 4Tumor Necrosis Factor-alphaItchKynurenine pathwayMicePsilocinPsilocybinPsychedelic

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.